These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27721530)

  • 1. Preclinical screening methods in cancer.
    Kumar S; Bajaj S; Bodla RB
    Indian J Pharmacol; 2016; 48(5):481-486. PubMed ID: 27721530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
    Telang N; Katdare M
    Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
    Frijhoff AF; Conti CJ; Senderowicz AM
    Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.
    Morfouace M; Nimmervoll B; Boulos N; Patel YT; Shelat A; Freeman BB; Robinson GW; Wright K; Gajjar A; Stewart CF; Gilbertson RJ; Roussel MF
    J Neurooncol; 2016 Jan; 126(2):225-34. PubMed ID: 26518542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
    Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
    Hansen K; Khanna C
    Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
    Suggitt M; Bibby MC
    Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons Learned from Two Decades of Anticancer Drugs.
    Liu Z; Delavan B; Roberts R; Tong W
    Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mighty mouse: genetically engineered mouse models in cancer drug development.
    Sharpless NE; Depinho RA
    Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests.
    Wang J; Dong H; Liu J; Zheng N; Xie X; Jia L
    Curr Cancer Drug Targets; 2019; 19(4):277-284. PubMed ID: 30117392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
    Olive KP; Tuveson DA
    Clin Cancer Res; 2006 Sep; 12(18):5277-87. PubMed ID: 17000660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
    Damia G; D'Incalci M
    Eur J Cancer; 2009 Nov; 45(16):2768-81. PubMed ID: 19762228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents.
    Li WT; Hwang DR; Song JS; Chen CP; Chuu JJ; Hu CB; Lin HL; Huang CL; Huang CY; Tseng HY; Lin CC; Chen TW; Lin CH; Wang HS; Shen CC; Chang CM; Chao YS; Chen CT
    J Med Chem; 2010 Mar; 53(6):2409-17. PubMed ID: 20170097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
    Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.